Abstract:The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta and protects IgG from degradation. Inhibition of this receptor results in both lysosomal degradation and prevention of cross‐placental transport, with a subsequent reduction in circulating IgG levels. FcRn inhibition does not impact the production of IgG, nor alter the levels of other immunoglobulin isotypes. Clinical trial data have thus far demonstrated that the risk of serious adverse events, including serious infections, appears to be lower than that seen with other commonly used immunomodulatory/immunosuppressive therapies. As such, FcRn inhibition represents a potential therapy for IgG‐mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, immune thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell/platelet alloimmunization). This review summarizes the current evidence and highlights potential reasons why FcRn inhibitors may be a potential treatment option for a variety of hematologic conditions. The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta and protects IgG from degradation. Numerous clinical trials are investigating therapeutic FcRn inhibition for various immune‐mediated neuromuscular and rheumatologic conditions; however, FcRn inhibition also represents a potential therapy for IgG‐mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, immune thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell/platelet alloimmunization). Current evidence derived from both in vitro and in vivo studies suggests that FcRn inhibitors effectively reduce total IgG levels without impacting its production or altering the levels of other immunoglobulin isotypes. Moreover, the risk of serious adverse events, including serious infections, appears to be lower than that seen with other commonly used immunomodulatory/immunosuppressive therapies, albeit in the setting of limited clinical trial data. Ultimately, additional clinical trials that include varied patient populations are required prior to incorporating these agents into standard treatment algorithms for most hematologic conditions. However, based on the pathophysiology of IgG‐mediated hematologic disorders and the mechanism of action of FcRn inhibitors, these agents may represent a future novel therapeutic strategy for patients with hematologic conditions caused by IgG antibodies.

Presence and possible impact of Fcγ receptors on resident kidney cells in health and disease

Fc gamma receptors: Their evolution, genomic architecture, genetic variation, and impact on human disease

Neonatal Fc Receptor Stimulation Induces Ubiquitin C-Terminal Hydrolase-1 Overexpression in Podocytes Through Activation of P38 Mitogen-Activated Protein Kinase

The therapeutic age of the neonatal Fc receptor

Expression of Neonatal Fc Receptor on Human Nephritis and Rat Nephritis Models

Current development of Fc gamma receptors (FcγRs) in diagnostics: a review

Presence of foam cells in kidney interstitium is associated with progression of renal injury in patients with glomerular diseases.

Regulation of immune responses by the neonatal fc receptor and its therapeutic implications

FcγRIIIb Inhibits Renal Transplant Rejection by Inducing Neutrophils Apoptosis

The Neonatal Fc Receptor (FcRn): A Misnomer?

Expression of Immunoglobulin G in Human Podocytes, and Its Role in Cell Viability and Adhesion

Role of the Innate Immune Response in Glomerular Disease Pathogenesis: Focus on Podocytes

Understanding the podocyte immune responses in proteinuric kidney diseases: from pathogenesis to therapy

Fc Receptor Targeting in the Treatment of Allergy, Autoimmune Diseases and Cancer

Fc gamma receptors are expressed in the developing rat brain and activate downstream signaling molecules upon cross-linking with immune complex

The role of immunoglobulin transport receptor, neonatal Fc receptor in mucosal infection and immunity and therapeutic intervention

GPCRs overexpression and impaired fMLP-induced functions in neutrophils from chronic kidney disease patients

Albumin influences leucocyte FcRn expression in the early days of kidney transplantation

Inflammasome Activation in Podocytes: a New Mechanism of Glomerular Diseases

γδ T cells in immune-mediated kidney disease

Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions